DC therapy after low-dose chemotherapy

Fumiaki Tanaka, Hiroshi Yamaguchi, Mitsuhiko Ota, Hiroshi Inoue, Masaki Mori

Research output: Contribution to journalArticle

Abstract

DC therapy is now considered to be one of the weapons with which to fight against a variety of cancers. We have investigated the in vivo antitumor effects of intratumoral (i.t.) administration of dendritic cells (DC) following low-dose chemotherapy. Combination of i.t. injection of DC and systemic chemotherapy induced antitumor effects on not only the DC-treated tumor but also on a distant tumor inoculated in the contralateral flank of the animal. To analyze the mechanisms of the systemic antitumor effect induced in this system, we analyzed the cytolytic activity against tumors including injected tumors and others. The cytolytic activity of effector cells from the treated animals was tumor-specific, and was mainly restricted to CD 8 and MHC class I (p<0.01). This study suggests that the strategy of i.t. injection of DC following low-dose chemotherapy could be a powerful weapon to treat patients with cancer in the near future.

Original languageEnglish
Pages (from-to)9-14
Number of pages6
JournalBiotherapy
Volume17
Issue number1
Publication statusPublished - Jan 1 2003

Fingerprint

Cell- and Tissue-Based Therapy
Dendritic Cells
Drug Therapy
Neoplasms
Weapons
Injections

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Tanaka, F., Yamaguchi, H., Ota, M., Inoue, H., & Mori, M. (2003). DC therapy after low-dose chemotherapy. Biotherapy, 17(1), 9-14.

DC therapy after low-dose chemotherapy. / Tanaka, Fumiaki; Yamaguchi, Hiroshi; Ota, Mitsuhiko; Inoue, Hiroshi; Mori, Masaki.

In: Biotherapy, Vol. 17, No. 1, 01.01.2003, p. 9-14.

Research output: Contribution to journalArticle

Tanaka, F, Yamaguchi, H, Ota, M, Inoue, H & Mori, M 2003, 'DC therapy after low-dose chemotherapy', Biotherapy, vol. 17, no. 1, pp. 9-14.
Tanaka F, Yamaguchi H, Ota M, Inoue H, Mori M. DC therapy after low-dose chemotherapy. Biotherapy. 2003 Jan 1;17(1):9-14.
Tanaka, Fumiaki ; Yamaguchi, Hiroshi ; Ota, Mitsuhiko ; Inoue, Hiroshi ; Mori, Masaki. / DC therapy after low-dose chemotherapy. In: Biotherapy. 2003 ; Vol. 17, No. 1. pp. 9-14.
@article{db07063774314a8f863dd1a236d286c9,
title = "DC therapy after low-dose chemotherapy",
abstract = "DC therapy is now considered to be one of the weapons with which to fight against a variety of cancers. We have investigated the in vivo antitumor effects of intratumoral (i.t.) administration of dendritic cells (DC) following low-dose chemotherapy. Combination of i.t. injection of DC and systemic chemotherapy induced antitumor effects on not only the DC-treated tumor but also on a distant tumor inoculated in the contralateral flank of the animal. To analyze the mechanisms of the systemic antitumor effect induced in this system, we analyzed the cytolytic activity against tumors including injected tumors and others. The cytolytic activity of effector cells from the treated animals was tumor-specific, and was mainly restricted to CD 8 and MHC class I (p<0.01). This study suggests that the strategy of i.t. injection of DC following low-dose chemotherapy could be a powerful weapon to treat patients with cancer in the near future.",
author = "Fumiaki Tanaka and Hiroshi Yamaguchi and Mitsuhiko Ota and Hiroshi Inoue and Masaki Mori",
year = "2003",
month = "1",
day = "1",
language = "English",
volume = "17",
pages = "9--14",
journal = "Biotherapy",
issn = "0914-2223",
publisher = "Japanese Society for Cancer Chemotherapy",
number = "1",

}

TY - JOUR

T1 - DC therapy after low-dose chemotherapy

AU - Tanaka, Fumiaki

AU - Yamaguchi, Hiroshi

AU - Ota, Mitsuhiko

AU - Inoue, Hiroshi

AU - Mori, Masaki

PY - 2003/1/1

Y1 - 2003/1/1

N2 - DC therapy is now considered to be one of the weapons with which to fight against a variety of cancers. We have investigated the in vivo antitumor effects of intratumoral (i.t.) administration of dendritic cells (DC) following low-dose chemotherapy. Combination of i.t. injection of DC and systemic chemotherapy induced antitumor effects on not only the DC-treated tumor but also on a distant tumor inoculated in the contralateral flank of the animal. To analyze the mechanisms of the systemic antitumor effect induced in this system, we analyzed the cytolytic activity against tumors including injected tumors and others. The cytolytic activity of effector cells from the treated animals was tumor-specific, and was mainly restricted to CD 8 and MHC class I (p<0.01). This study suggests that the strategy of i.t. injection of DC following low-dose chemotherapy could be a powerful weapon to treat patients with cancer in the near future.

AB - DC therapy is now considered to be one of the weapons with which to fight against a variety of cancers. We have investigated the in vivo antitumor effects of intratumoral (i.t.) administration of dendritic cells (DC) following low-dose chemotherapy. Combination of i.t. injection of DC and systemic chemotherapy induced antitumor effects on not only the DC-treated tumor but also on a distant tumor inoculated in the contralateral flank of the animal. To analyze the mechanisms of the systemic antitumor effect induced in this system, we analyzed the cytolytic activity against tumors including injected tumors and others. The cytolytic activity of effector cells from the treated animals was tumor-specific, and was mainly restricted to CD 8 and MHC class I (p<0.01). This study suggests that the strategy of i.t. injection of DC following low-dose chemotherapy could be a powerful weapon to treat patients with cancer in the near future.

UR - http://www.scopus.com/inward/record.url?scp=0037284365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037284365&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 9

EP - 14

JO - Biotherapy

JF - Biotherapy

SN - 0914-2223

IS - 1

ER -